From the American Academy of Ophthalmology

Investigators evaluated the progression of retinal pigment epithelium (RPE) and choroidal atrophy among 415 eyes with wet AMD, using fellow eyes with nonneovascular AMD as controls. At a mean follow-up of two years, eyes with wet AMD had greater progression of RPE atrophy and choroidal atrophy compared with controls (P < 0.001). Atrophy progression was independently associated with the total number of injections of bevacizumab and ranibizumab (all P values ≤ 0.001). Additionally, they observed a possible difference between bevacizumab and ranibizumab for RPE atrophy. Retina, July 2014